Refining prognosis in advanced renal cell carcinoma: international real-world validation of the Meet-URO score in first-line immunotherapy combinations
The Oncologist · 06.06.2026 · 31 (7)
DOI: 10.1093/oncolo/oyag203 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Oncologist, online erschienen am 20.05.2026. Verfasst von Sara Elena Rebuzzi und 59 weiteren Autor:innen. Beteiligte Einrichtung: Medical Oncology Unit 2, Ospedale Molinette, Azienda Ospedaliero-Universitaria Città della Salute e della Scienza di Torino, Torino, 10126, Italy. Hauptthemen laut MEDLINE: Carcinoma, Renal Cell, Kidney Neoplasms, Immunotherapy. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Effective risk stratification is essential for guiding treatment decisions in patients with metastatic renal cell carcinoma (mRCC). The Meet-URO score is a novel prognostic model that integrates the International Metastatic RCC Database Consortium (IMDC) criteria with neutrophil-to-lymphocyte ratio (NLR) and the presence of bone metastases. Developed in the immunotherapy era, it has demonstrated superior prognostic accuracy compared to the IMDC score across various clinical settings and treatment strategies. Its validation in the context of first-line immune-based combinations has been awaited.
Methods
External validation of Meet-URO was performed using a large retrospective real-world cohort of mRCC patients treated with first-line immune-based combinations. Secondary analyses included a comparison with the IMDC score for predicting overall survival (OS) and progression-free survival (PFS). Additionally, restricted mean survival time (RMST) was assessed.
Results
A total of 1,418 patients were included in the analysis: 54% received ICI–ICI regimen (nivolumab plus ipilimumab), while 46% received the ICI–TKI combination. At baseline, 52.5% of patients had an NLR ≥ 3.2, and 32% had bone metastases. After a median follow-up of 26.8 months, the median OS and median PFS were 34.7 and 11.3 months, respectively. Meet-URO demonstrated effective prognostic stratification, identifying patient groups with markedly different outcomes (median OS 11.5-51.4 months; 3-year OS 26-66%; RMST 20.0-42.8 months). Compared to IMDC, Meet-URO showed a significantly better OS (c-index 0.675 vs 0.643; Δc = 0.032, P < .001) and PFS (c-index 0.60 vs 0.58; P < .001) prediction performance.
Conclusions
Meet-URO demonstrated robust prognostic accuracy. Its integration into routine clinical practice and use as a stratification factor in clinical trials may support more personalized treatment strategies and enhance clinical trial design.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Medical Oncology Unit 2, Ospedale Molinette, Azienda Ospedaliero-Universitaria Città della Salute e della Scienza di Torino, Torino, 10126, Italy.
- Barts Cancer Centre, Barts Health NHS Trust, London, EC1A 7BE, United Kingdom.
- Cancer Centre at Guy's, Guy's and St Thomas' NHS Foundation Trust, London, SE1 9RT, United Kingdom.
- Beatson West of Scotland Cancer Centre, NHS Greater Glasgow and Clyde, Glasgow, G12 0YN, United Kingdom.
- Department of Medical Oncology, The Royal Marsden NHS Foundation Trust, London, SW3 6JJ, United Kingdom.
- Velindre Cancer Centre, Velindre University NHS Trust, Cardiff, CF14 2TL, United Kingdom.
ORCID-Profile: Fabrizio Di Costanzo
Zitieren
APA
Rebuzzi, S. E., Ghose, A., Rudman, S., Venugopal, B., Young, K., Frazer, R. D., Ayodele, O., Stares, M., O'Carrigan, B., Ali, W., McGrane, J., Jain, A., Fiala, O., Chauhan, V., Michael, A., Zarkar, A., Kapur, G., Charnley, N., Afshar, M., …, & Leung, D. K. (2026). Refining prognosis in advanced renal cell carcinoma: international real-world validation of the Meet-URO score in first-line immunotherapy combinations. The Oncologist, 31(7). https://doi.org/10.1093/oncolo/oyag203
Vancouver
Rebuzzi SE, Ghose A, Rudman S, Venugopal B, Young K, Frazer RD, et al. Refining prognosis in advanced renal cell carcinoma: international real-world validation of the Meet-URO score in first-line immunotherapy combinations. The Oncologist. 2026;31(7). doi:10.1093/oncolo/oyag203
BibTeX
@article{Rebuzzi2026,
author = {Rebuzzi, Sara Elena and Ghose, Aruni and Rudman, Sarah and Venugopal, Balaji and Young, Kate and Frazer, Ricky Dylan and Ayodele, Olubukola and Stares, Mark and O'Carrigan, Brent and Ali, Waqas and McGrane, John and Jain, Ankit and Fiala, Ondrej and Chauhan, Vishwani and Michael, Agnieszka and Zarkar, Anjali and Kapur, Gaurav and Charnley, Natalie and Afshar, Mehran and Vengalil, Salil and Forde, Caroline and Brown, Janet and Ürün, Yüksel and Bianchini, Diletta and Bahl, Amit and Srihari, Narayanan and Di Costanzo, Fabrizio and Smalley, Benjamin and Parkes, Joanne and Crabb, Simon and Vasudev, Naveen and Poprach, Alexandr and Brown, Nicholas and James, Lijo and Haywood, Sophia and Tapia, Jose and Vijay, Anupama and Parry, Jane and Cheung, Michael and Mahajan, Ishika and Moon, Niall O and Abrol, Ritika and Tkadlecová, Michaela and Soe, Yamin Shwe Yee and Zargham, Anum and Smith, Michelle and Ashley, Sophie and Hardy, Orla and Patel, Grisma and Tun, Kyaw Kyaw and Johnston, Emma and Sarwer, Abdullah and Bölek, Hatice and Shrestha, Roshani and Challapalli, Amarnath and Meegan, James and Anpalakhan, Shobana and Buono, Francesco and Kolarikova, Eva and Leung, David Ka-Wai},
title = {Refining prognosis in advanced renal cell carcinoma: international real-world validation of the Meet-URO score in first-line immunotherapy combinations},
journal = {The Oncologist},
year = {2026},
volume = {31},
number = {7},
doi = {10.1093/oncolo/oyag203}
}
EUVIMED